Fibronectin extra domain B-specific aptide conjugated nanoparticles for targeted cancer imaging

Park, Jinho; Kim, Sung-Hyun; Saw, Phei Er; Lee, In Hyun; Yu, Mi; Kim, Minsik; Lee, Kwangyeol; Kim, Yong Chul; Jeong, Yong Yeon; Jon, Sangyong

doi:10.1016/j.jconrel.2012.08.029

Cited by 42 publications

(23 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our previous studies have shown that the small size high-affinity peptide aptide (APT EDB ) can easily extravasate and specifically bind to EDB-FN as a targeting ligand for the delivery of a drug-encapsulating liposome for cancer therapy 22. To allow the selective detection of EDB-FN-expressing tumors via in vivo MRI, we recently synthesized oleic acid-stabilized SPIONs by conjugating them with APT EDB 21. Previous reports have considered APT EDB a desirable moiety for the selective and effective detection of EDB-FN.…”

Section: Discussionmentioning

confidence: 99%

“…We have further reported a technology that enables us to screen and identify a novel class of high-affinity peptides ('aptides') for various biological targets 20. Using this platform technology, we have identified a high-affinity high-specificity peptide ligand for EDB-FN, which we designated APT EDB , that is 26 amino acids long and has several tens of nM affinity for the EDB-FN protein 21, 22.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

MRI of Breast Tumor Initiating Cells Using the Extra Domain-B of Fibronectin Targeting Nanoparticles

Sun¹,

Kim²,

Park³

et al. 2014

Theranostics

Self Cite

View full text Add to dashboard Cite

The identification of breast tumor initiating cells (BTICs) is important for the diagnosis and therapy of breast cancers. This study was undertaken to evaluate whether the extra domain-B of fibronectin (EDB-FN) could be used as a new biomarker for BTICs and whether EDB-FN targeting superparamagnetic iron oxide nanoparticles (SPIONs) could be used as a magnetic resonance imaging (MRI) contrast agent for BTIC imaging in vitro and in vivo. BTICs (NDY-1) exhibited high EDB-FN expression, whereas non-BTICs (MCF-7, BT-474, SUM-225, MDA-MB-231) did not exhibit EDB-FN expression. Furthermore, Cy3.3-labeled EDB-FN specific peptides (APTEDB) showed preferential binding to the targeted NDY-1 cells. To construct an EDB-FN targeted imaging probe, APTEDB was covalently attached to a thermally cross-linked SPION (TCL-SPION) to yield APTEDB-TCL-SPION. In the in vitro MRI of cell phantoms, selective binding of APTEDB-TCL-SPION to NDY-1 cells was evident, but little binding was observed in MCF-7 cells. After the intravenous injection of APTEDB-TCL-SPION into the NDY-1 mouse tumor xenograft model, a significant decrease in the signal within the tumor was observed in the T2*-weighted images; however, there was only a marginal change in the signal of non-targeting SPIONs such as APTscramble-TCL-SPION or TCL-SPION. Taken together, we report for the first time that EDB-FN was abundantly expressed in BTICs and may therefore be useful as a new biomarker for identifying BTICs. Our study also suggests that APTEDB-TCL-SPION could be used as an MRI contrast agent for BTIC imaging.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

MRI of Breast Tumor Initiating Cells Using the Extra Domain-B of Fibronectin Targeting Nanoparticles

Sun¹,

Kim²,

Park³

et al. 2014

Theranostics

Self Cite

View full text Add to dashboard Cite

show abstract

“…Vascular targeting of SPIO agents to integrins [110] or VEGFR [114] has been exploited for imaging of tumor-associated vasculature. Deep tissue targeting with SPIOs has also been explored to image primary tumors using targets such as urokinase plaminogen activator (uPA) [111, 112], transferrin receptors [115], HER2 receptors [172], chemokine receptor 4 [113]. …”

Section: Targeted Nanoparticle Imaging Agentsmentioning

confidence: 99%

Targeted nanotechnology for cancer imaging

Toy

Bauer

Hoimes

et al. 2014

Advanced Drug Delivery Reviews

167

100

View full text Add to dashboard Cite

Targeted nanoparticle imaging agents provide many benefits and new opportunities to facilitate accurate diagnosis of cancer and significantly impact patient outcome. Due to the highly engineerable nature of nanotechnology, targeted nanoparticles exhibit significant advantages including increased contrast sensitivity, binding avidity and targeting specificity. Considering the various nanoparticle designs and their adjustable ability to target a specific site and generate detectable signals, nanoparticles can be optimally designed in terms of biophysical interactions (i.e., intravascular and interstitial transport) and biochemical interactions (i.e., targeting avidity towards cancer-related biomarkers) for site-specific detection of very distinct microenvironments. This review seeks to illustrate that the design of a nanoparticle dictates its in vivo journey and targeting of hard-to-reach cancer sites, facilitating early and accurate diagnosis and interrogation of the most aggressive forms of cancer. We will report various targeted nanoparticles for cancer imaging using X-ray computed tomography, ultrasound, magnetic resonance imaging, nuclear imaging and optical imaging. Finally, to realize the full potential of targeted nanotechnology for cancer imaging, we will describe the challenges and opportunities for the clinical translation and widespread adaptation of targeted nanoparticles imaging agents.

show abstract

“…Meanwhile, a research by Park et al [82] reported the development of novel high-affinity peptides that target a variety of protein targets. The peptides were integrated in superparamagnetic iron oxide NPs for the targeting of fibronectin extra domain B (EDB).…”

Section: Conjugation Of Biomoleculesmentioning

confidence: 99%

“…The rhodamine dye family is one of the most common luminescent probes used for the detection of cancer cells. Different types of rhodamine dyes including rhodamine B, rhodamine 123, and rhodamine 6G have been extensively conjugated to stimulus-responsive NPs in research to illustrate the effectiveness of their NPs in targeting tumor sites [79,81,82,83]. Such incorporation of fluorescent dyes also serves to provide an MRI contrasting agent for the sole purpose of imaging.…”

Section: Conjugation Of Biomoleculesmentioning

confidence: 99%

Development and Characterization of Stimulus-Sensitive Nano/Microparticles for Medical Applications

Menon

Nguyen

2016

Handbook of Nanoparticles

View full text Add to dashboard Cite

Fibronectin extra domain B-specific aptide conjugated nanoparticles for targeted cancer imaging

Cited by 42 publications

References 35 publications

MRI of Breast Tumor Initiating Cells Using the Extra Domain-B of Fibronectin Targeting Nanoparticles

MRI of Breast Tumor Initiating Cells Using the Extra Domain-B of Fibronectin Targeting Nanoparticles

Targeted nanotechnology for cancer imaging

Development and Characterization of Stimulus-Sensitive Nano/Microparticles for Medical Applications

Contact Info

Product

Resources

About